Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.

[1]  B. Conway,et al.  Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. , 2017, The International journal on drug policy.

[2]  J. Macías,et al.  HCV epidemiology in high-risk groups and the risk of reinfection. , 2016, Journal of hepatology.

[3]  D. Nickle,et al.  Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. , 2016, Annals of internal medicine.

[4]  M. Alavi,et al.  Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. , 2016, Addiction.

[5]  D. De Angelis,et al.  Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence , 2015, Current opinion in infectious diseases.

[6]  M. Alavi,et al.  Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. , 2015, The International journal on drug policy.

[7]  M. Hellard,et al.  Recommendations for the management of hepatitis C virus infection among people who inject drugs. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Aasld Idsa Hcv Guidance Panel.  Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.

[9]  M. Alavi,et al.  Continued low uptake of treatment for hepatitis C virus infection in a large community‐based cohort of inner city residents , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[10]  M. Abrahamowicz,et al.  Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  H. Wand,et al.  Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011 , 2014, Journal of viral hepatitis.

[12]  A. Pharris,et al.  Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. , 2014, The International journal on drug policy.

[13]  G. Dore,et al.  Epidemiology and natural history of HCV infection , 2013, Nature Reviews Gastroenterology &Hepatology.

[14]  M. Schaefer,et al.  Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Hellard,et al.  Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  P. Vickerman,et al.  Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  H. Innes,et al.  Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. , 2013, The International journal on drug policy.

[18]  K. Kielland,et al.  All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. , 2013, Journal of hepatology.

[19]  P. Bruggmann.  Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers , 2012, Journal of viral hepatitis.

[20]  D. D. Des Jarlais,et al.  Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. , 2012, Addiction.

[21]  C. Mcgowan,et al.  Barriers to hepatitis C treatment , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[22]  G. Dore,et al.  Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. , 2011, Addiction.

[23]  Jing Zhao,et al.  Physicians’ attitudes and practice toward treating injection drug users infected with hepatitis C virus: Results from a national specialist survey in Canada , 2011 .

[24]  J. Raffa,et al.  Impact of hepatitis C virus infection on all‐cause and liver‐related mortality in a large community‐based cohort of inner city residents , 2011, Journal of viral hepatitis.

[25]  Judy Gold,et al.  Hepatitis C treatment for injection drug users: a review of the available evidence. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Kenneth A. Harris,et al.  Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. , 2009, Journal of substance abuse treatment.

[27]  J. Raffa,et al.  Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residents , 2009, Journal of viral hepatitis.

[28]  Laurent Castera,et al.  Non-invasive evaluation of liver fibrosis using transient elastography. , 2008, Journal of hepatology.

[29]  S. Mauss,et al.  A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance , 2004, Hepatology.

[30]  S. Creech,et al.  Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse , 2003, American Journal of Gastroenterology.

[31]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[32]  D. Kivlahan,et al.  The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. , 1998, Archives of internal medicine.

[33]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.